MAPT and Alzheimer disease: Today, the AD diagnosis relies on a combination of clinical, imaging, and laboratory criteria[4,5] the latter being cerebrospinal fluid (CSF) levels of amyloid beta 1-42 peptide (Aβ1-42), tau protein (t-tau), and tau specifically phosphorylated at Thr-181 (p-tau181).